HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
The Week

ASCO '26: Bispecifics vs. ADCs, a 'RAS' revolution and a step change in prostate cancer

At the year's biggest cancer meeting, a high-stakes clash between two popular drug classes erupted, and scientists made headway against a once-insurmountable foe.

By BioPharma Dive · Jun 2, 2026 · via BioPharma Dive
ASCO '26: Bispecifics vs. ADCs, a 'RAS' revolution and a step change in prostate cancer

Image: BioPharma Dive

This is an aggregated industry headline. Read the full story at BioPharma Dive →

Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
Eisai whips up Alzheimer's dietary guidance to expand nutrition program beyond cancer
The WeekFiercePharma ↗
Eisai whips up Alzheimer's dietary guidance to expand nutrition program beyond cancer
Eisai has partnered with CaringKind to expand its nutrition support initiative to cover Alzheimer's disease an…
Jun 2, 2026
Praxis pauses one of its seizure programs after phase 2 fail
The WeekFierceBiotech ↗
Praxis pauses one of its seizure programs after phase 2 fail
Praxis Precision Medicines' epilepsy pipeline has suffered a setback after a next-gen NaV blocker failed to su…
Jun 2, 2026
Abivax’s Phase 3 Triumph Turns Risk Event as Cancer Cases Emerge
The WeekBriefing
Abivax’s Phase 3 Triumph Turns Risk Event as Cancer Cases Emerge
Obefazimod delivered industry-leading remission rates in ulcerative colitis, but new cancer cases wiped out th…
Jun 2, 2026